Literature DB >> 15784570

Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia.

Andrew Y Koh1, Gregory P Priebe, Gerald B Pier.   

Abstract

Pseudomonas aeruginosa bacteremia in cancer patients develops from initial gastrointestinal (GI) colonization with translocation into the bloodstream in the setting of chemotherapy-induced neutropenia and GI mucosal damage. We established a reproducible mouse model of P. aeruginosa GI colonization and systemic spread during neutropenia. Mice received 2 mg of streptomycin/ml of drinking water and 1,500 U of penicillin G/ml for 4 days and then ingested 10(7) CFU of P. aeruginosa per ml of drinking water for 5 days. After GI colonization levels were determined, cyclophosphamide (Cy) was then injected intraperitoneally (i.p.) three times every other day or an antineutrophil monoclonal antibody, RB6-8C5, was injected i.p. once. Dissemination was defined by the presence of P. aeruginosa in spleens of moribund or dead mice. In this mouse model, P. aeruginosa colonizes the GI tract and then disseminates systemically once Cy or RB6-8C5 is administered. The duration and intensity of neutropenia, related to Cy dose, was found to be a means to compare the virulence of different P. aeruginosa strains, as exhibited by comparisons of strains lacking or producing the virulence-enhancing ExoU cytotoxin. The lipopolysaccharide outer core polysaccharide and O side chains were critical in establishing GI colonization, and P. aeruginosa mutants lacking the aroA gene (necessary for synthesizing aromatic amino acids) were able to establish GI colonization but unable to disseminate. Both the colonization and dissemination phases of P. aeruginosa pathogenesis can be studied in this model, which should prove useful for evaluating pathogenesis, therapies, and associated means to control P. aeruginosa nosocomial infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15784570      PMCID: PMC1087461          DOI: 10.1128/IAI.73.4.2262-2272.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia.

Authors:  M Rubin; J W Hathorn; D Marshall; J Gress; S M Steinberg; P A Pizzo
Journal:  Ann Intern Med       Date:  1988-01       Impact factor: 25.391

2.  The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group.

Authors:  O D Schein; R J Glynn; E C Poggio; J M Seddon; K R Kenyon
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

3.  Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells.

Authors:  K Hestdal; F W Ruscetti; J N Ihle; S E Jacobsen; C M Dubois; W C Kopp; D L Longo; J R Keller
Journal:  J Immunol       Date:  1991-07-01       Impact factor: 5.422

4.  Gram-positive bacteraemia in granulocytopenic cancer patients.

Authors: 
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

5.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

6.  Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria.

Authors:  C L Wells; M A Maddaus; C M Reynolds; R P Jechorek; R L Simmons
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

Review 7.  Pseudomonas aeruginosa infection in cancer patients.

Authors:  K V Rolston; G P Bodey
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

Review 8.  Auxotrophic Salmonella typhi as live vaccine.

Authors:  B A Stocker
Journal:  Vaccine       Date:  1988-04       Impact factor: 3.641

9.  Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies.

Authors:  C H Tancrède; A O Andremont
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

10.  The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses.

Authors:  E C Poggio; R J Glynn; O D Schein; J M Seddon; M J Shannon; V A Scardino; K R Kenyon
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

View more
  36 in total

1.  MyD88-dependent signaling protects against anthrax lethal toxin-induced impairment of intestinal barrier function.

Authors:  Shu Okugawa; Mahtab Moayeri; Michael A Eckhaus; Devorah Crown; Sharmina Miller-Randolph; Shihui Liu; Shizuo Akira; Stephen H Leppla
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

Review 2.  Murine models of Candida gastrointestinal colonization and dissemination.

Authors:  Andrew Y Koh
Journal:  Eukaryot Cell       Date:  2013-09-13

3.  Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.

Authors:  Bryan J Berube; Katherine R Murphy; Matthew C Torhan; Nicholas O Bowlin; John D Williams; Terry L Bowlin; Donald T Moir; Alan R Hauser
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections.

Authors:  Leticia V Bentancor; Abhisek Routray; Cagla Bozkurt-Guzel; Ana Camacho-Peiro; Gerald B Pier; Tomás Maira-Litrán
Journal:  Infect Immun       Date:  2012-07-23       Impact factor: 3.441

5.  Bacterial infections in Myd88-deficient mice.

Authors:  Jason S Villano; Fang Rong; Timothy K Cooper
Journal:  Comp Med       Date:  2014-04       Impact factor: 0.982

6.  The Pseudomonas aeruginosa magnesium transporter MgtE inhibits transcription of the type III secretion system.

Authors:  Gregory G Anderson; Timothy L Yahr; Rustin R Lovewell; George A O'Toole
Journal:  Infect Immun       Date:  2009-12-22       Impact factor: 3.441

7.  Sugar administration is an effective adjunctive therapy in the treatment of Pseudomonas aeruginosa pneumonia.

Authors:  Iwona Bucior; Jason Abbott; Yuanlin Song; Michael A Matthay; Joanne N Engel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-06-21       Impact factor: 5.464

8.  Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model.

Authors:  Akinobu Kamei; Andrew Y Koh; Mihaela Gadjeva; Gregory P Priebe; Stephen Lory; Gerald B Pier
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

9.  Exogenous remodeling of lung resident macrophages protects against infectious consequences of bone marrow-suppressive chemotherapy.

Authors:  Akinobu Kamei; Geli Gao; Geoffrey Neale; Lip Nam Loh; Peter Vogel; Paul G Thomas; Elaine I Tuomanen; Peter J Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-26       Impact factor: 11.205

10.  Vaccination against Pseudomonas aeruginosa pneumonia in immunocompromised mice.

Authors:  Jennifer M Scarff; Joanna B Goldberg
Journal:  Clin Vaccine Immunol       Date:  2007-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.